MediWound's January 2025 investor presentation highlighted NexoBrid's status as an FDA, EMA, and Japan-approved orphan biologic for adult and pediatric burn eschar removal, with 2024 revenue of $20 million. The company noted a 3:1 demand to current production capacity, with a 6x manufacturing scale-up expected to be operational by year-end 2025.
The presentation also detailed EscharEx, an investigational therapy for chronic wounds, with a Phase III VLU trial set to initiate in Q1 2025 and Phase II/III DFU preparations underway, supported by €16.25 million in EIC funding. EscharEx targets a $2.5 billion U.S. market and challenges a $375 million+ dominant product.
Financially, MediWound reported $44 million in cash as of December 31, 2024, with no debt, and over $115 million received from BARDA and $15 million from the DoD. These funds provide a runway through profitability and support the company's diversified portfolio and strategic global collaborations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.